Clinical Trials Logo

Clinical Trial Summary

Investigate the efficacy and safety of mirogabalin in participants with central neuropathic pain in comparison to placebo


Clinical Trial Description

[Double Blind Phase] The primary objective is to compare change in the Average Daily Pain Score (ADPS) from baseline to Week 14 in Asian participants with central neuropathic pain (central neuropathic pain after spinal cord injury) receiving mirogabalin versus placebo. [Open Extension Phase] The objective is to assess the long-term safety and efficacy of mirogabalin in participants with central neuropathic pain (central neuropathic pain after spinal cord injury, central post stroke pain, and central neuropathic pain in Parkinson's disease). ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03901352
Study type Interventional
Source Daiichi Sankyo, Inc.
Contact
Status Completed
Phase Phase 3
Start date March 12, 2019
Completion date December 28, 2020

See also
  Status Clinical Trial Phase
Completed NCT01324232 - Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis Phase 2
Recruiting NCT06072001 - Long Term Efficacy and Tolerability of AP707 in Patients With Chronic Pain Due to Central Neuropathy of Any Genesis Phase 3
Recruiting NCT06071949 - Efficacy and Tolerability of AP707 in Patients With Chronic Pain Due to Central Neuropathy of Any Genesis Phase 3
Recruiting NCT05357066 - Nitrous Oxide as Treatment for Fibromyalgia Phase 2
Not yet recruiting NCT06422117 - Efficacy and Safety of HSK16149 Capsule in the Treatment of Moderate and Severe Central Neuropathic Pain in China Phase 3
Not yet recruiting NCT04665492 - EEG Predictors of Neuropathic Pain in SCI
Completed NCT00313820 - Efficacy Of Pregabalin In Subjects With Post-Stroke Central Neuropathic Pain Phase 4
Completed NCT02218203 - Clinical Neuropharmacology of Pain in Spinal Cord Injury- Dextromethorphan/Lidocaine Combination Clinical Trial Phase 2